We here present the results of immunohistochemistry (IHC) analyses in tumour tissue on PI3K/MAPK pathway activation from 145 MBC patients that received standard EVE/EXE in an attempt to find a potential marker helpful to select patients for this type of treatment. This evidence concerns the gene PIK3CA and neoplasm.